SK Chemicals signed a deal to market Sanofi Pasteur's Menactra, a meningococcal conjugate vaccine, and a live-attenuated Japanese encephalitis vaccine upon approval, in South Korea.
Sanofi will provide SK Chemicals with the vaccines, which then will be promoted and distributed for treatment of adult patients through SK Chemicals.
Menactra is a 4-valent protein-conjugate vaccine preventing meningococcal meningitis caused by 4 serogroups (A, C, Y, W-135) of meningococcal bacteria.
It is the first vaccine in its class to obtain U.S. FDA approval in 2005 with more than 70 million doses provided throughout 53 countries. It is the most-sold meningococcal protein-conjugate vaccine in the world. It has a proven rate of immunogenicity of over 98% against 4 serogroups in clinical trials carried out in the U.S.
Cell culture-derived Japanese encephalitis vaccine (live) awaits approval from the Korean Food and Drug Administration.
- read the release